National and Kapodistrian University of Athens
Οστικός μεταβολισμός σε ασθενείς με καρδιακή ανεπάρκεια στεφανιαίας και μη αιτιολογίας
Abstract
dc:descriptionBackground: Chronic heart failure (CHF) and osteoporosis are two highly prevalent diseases particularly among the elderly, with significant morbidity and mortality. These two chronic disorders share many common risk factors, such as older age, excessive use of tobacco and alcohol, diabetes. Furthermore, CHF causes many metabolic disturbances, which negatively affect bone metabolism and exacerbates bone loss. Recent evidence supports the fact that CHF patients are at increased risk of osteoporosis and orthopaedic fractures. Aims: The aim of the present study was to investigate the relationship between severity of CHF and bone loss, the underlying pathophysiological mechanisms, and the prognostic significance of bone mass changes and bone metabolism parameters in heart failure.Methods: Total body (TB) and femoral (F) bone mineral density (BMD), and T- and Z-scores in femur were measured in 60 men with CHF (56+11 years) and 13 age-matched men free from CHF. The composite study endpoint was death, implantation of a left ventricular assist device (LVAD), or inotrope dependency during a median 2-year follow-up. Parathyroid hormone (PTH), vitamin D, interleukin 6 (IL6), bone alkaline phosphatase (bALP) and carboxy terminal cross links (β-CTx) were measured in serum of all subjects. Results: TBBMD, FBMD, T-score, and Z-score were significantly lower and PTH levels were significantly higher in men with CHF. Patients in NYHA classes III–IV compared with those in classes I–II demonstrated significantly lower TBBMD, FBMD, T-score, and Z-score, and higher PTH. Increased PTH levels were correlated with reduced TBBMD (p:0,003), FBMD (p:0,002), and femur T-score (p:0,001), reduced cardiac index (p:0,01) and VO2 peak (p:0,0001), and increased wedge pressure (p:0,001). Moreover, increased PTH in CHF patients was significantly associated with reduced vitamin D (p:0,01), increased bALP (p:0,01), increased β-CTx (p:<0,001) and increased IL6 (p:0,006). Although vitamin D levels were lower in CHF patients and particularly in NYHA III-IV classes, the difference did not reach statistical significance. BALP levels were higher in NYHA III-IV patients and correlated with the NYHA classification, and were also significantly associated with reduced BMD in total body and femur measurements. The increase in β-CTx was even more strikingly correlations with NYHA classification and cardiovascular indices of CHF severity (ejection fraction, wedge pressure, VO2 peak, BNP), as well as with low BMD (total body and femur) measurements. Finally, IL6 levels were higher in CHF patients and were associated significantly with NYHA severity and other cardiovascular indices (BNP, wedge pressure, ejection fraction, cardiac index, VO2 peak), but not correlated with the reduction of BMD. According to the standard definition of cardiac cachexia, 9 out of 60 patients (15%) were in cachectic status (NYHA III, IV: 4/5). Cachectic patients had significantly increased BNP (p:0,001), increased wedge pressure (p:0,003) and reduced cardiac index (p:0,03). They presented with significant differences (reduction) in all three body compartments (bone, lean, fat tissue), either in total body or in specific regions of the body. TBBMD (p:0,002) and FBMD (p:0,004) were significantly associated with the presence of cachexia. ROC curve analysis showed that TBBMD (AUC: 0,804 and p:0,004) and FBMD (AUC: 0,82 and p:0,005) could identify cachectic patients. Values of TBBMD < 1,150 g/cm2 discriminate cachectic patients with sensitivity of 67% and specificity of 86%. Values of FBMD < 0,786 g/cm2 identify cachectic patients with sensitivity of 63% and specificity of 78%.During 2 years of follow up, 11 patients died, in 3 patients LVAD was implanted and 5 patients became inotrope dependent. Low TBBMD [hazard ratio (HR) 0,003 ; 95% confidence interval (CI) 0,00–0,58 ; p:0,03] and Z-score (HR 0,56 ; 95% CI 0,35–0,90 ; p:0,017) were associated with adverse outcome. High β-CTx levels were also associated with increased morbidity and mortality (HR 6,32 ; 95% CI 1,77–22,54 ; p:0,005). The presence of cachexia had independent prognostic value for adverse outcome (HR 5,86 ; 95% CI 2,15–16,01 ; p:0,001). Conclusions Secondary hyperparathyroidism and reduction in bone density occur in CHF patients and are associated with disease severity. Secondary hyperparathyroidism maybe the underlying pathophysiologic mechanism of reduced bone density in CHF, by accelerating bone turn over, especially the catabolic component. Increased bone mass loss and osteoclastic activity in CHF have prognostic significance. Patients in advanced stages of CHF are at increased risk of developing cachexia, which is characterized by reduction in bone, lean and fat tissue, and is related with unfavourable outcome. TBBMD and FBMD are strongly associated with the presence of cachexia and could be valuable tools for distinguishing patients at risk for cachexia.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2012
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Zotos, Panagiotis
- Ζώτος, Παναγιώτης
Subjects
dc:subject × 20- Χρόνια καρδιακή ανεπάρκεια
- Οστικός μεταβολισμός
- Οστεοπόρωση
- Υπερπαραθυρεοειδισμός
- Καχεξία
- Οστική πυκνότητα
- Θνησιμότητα
- Θνητότητα
- Chronic heart failure
- Bone metabolism
- Osteoporosis
- Hyperparathyroidism
- Cachexia
- Bone density
- Morbidity
- Mortality
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/29709